LLY Eli Lilly and Company
Company Analysis
Latest News
JPMorgan Raises Eli Lilly Price Target to $1,150 Citing Obesity Drug Strength
JPMorgan has increased its price target for Eli Lilly to $1,150 from $1,050, reiterating an Overweight rating on the stock. The investment bank's optimism is...
Eli Lilly Receives Approval for Alzheimer's Drug Donanemab in India, JPMorgan Raises Price Target
Eli Lilly has received marketing authorization from India's Central Drugs Standard Control Organization for donanemab, its treatment for early symptomatic...
Eli Lilly Announces $2.6 Billion Multi-Program Collaboration with ABL Bio
On November 18, 2025, Eli Lilly announced a $2.6 billion multi-program collaboration agreement with ABL Bio to develop therapeutics using ABL Bio’s Grabody...
Eli Lilly Receives Approval for Alzheimer's Drug Donanemab in India
Eli Lilly and Company has received marketing authorization from India's Central Drugs Standard Control Organization (CDSCO) for its Alzheimer's treatment,...
JPMorgan Raises Eli Lilly Price Target to $1150 on Strong Obesity Drug Outlook
JPMorgan has increased its price target for Eli Lilly stock to $1,150 from $1,050, while reiterating an "Overweight" rating. The updated forecast came after...
JP Morgan Raises Eli Lilly Price Target to $1150 Amid Strong Drug Portfolio Momentum
On November 18, 2025, JP Morgan raised its price target for Eli Lilly (LLY) to $1150, reflecting increased confidence in the company's growth prospects and...
Eli Lilly's Alzheimer's Drug Donanemab Gains Approval in India
Eli Lilly and Company announced it has received marketing authorization for its Alzheimer's drug, donanemab, from India's Central Drugs Standard Control...
LLY Drops After Novo Nordisk Slashes Obesity Drug Prices
On November 17, 2025, Eli Lilly (LLY) shares declined after Novo Nordisk announced significant price reductions for its weight-loss drugs Wegovy and Ozempic,...
Eli Lilly Strikes $2.6 Billion Licensing Deal with ABL Bio for Antibody Technology
Eli Lilly and Company has entered into a significant licensing and joint research agreement with South Korean biotech firm ABL Bio for its bispecific antibody...
Eli Lilly's Blockbuster Drugs Single-Handedly Drive Ireland's 2025 GDP Growth by 11%
A report from The Irish Times on November 12, 2025, revealed that Eli Lilly's blockbuster weight-loss drugs, Mounjaro and Zepbound, are the primary drivers...
Eli Lilly Surges on Strategic R&D Shift, Hits New Highs
On November 11, 2025, Eli Lilly shares surged 4.54% in pre-market trading following announcements of a strategic expansion in diabetes and oncology R&D, and a...
Eli Lilly and Novo Nordisk Strike Deal with Trump Administration to Lower GLP-1 Drug Prices
Eli Lilly and Company, along with competitor Novo Nordisk, has reached an agreement with the Trump administration to substantially reduce the prices of their...
Eli Lilly Stock Hits Record Highs Amid Analyst Actions and Strong Q3
On November 10, 2025, Eli Lilly (LLY) stock closed at $966.64, up 4.57%, marking a new all-time high and reflecting strong investor enthusiasm[3]. The surge...
Eli Lilly Expands into Gene Therapy and RNAi with Strategic Collaborations
Eli Lilly and Company announced significant strategic collaborations to expand its pipeline into genetic medicines. The company partnered with MeiraGTx to...
Eli Lilly Expands into Ophthalmic Gene Therapy with $475M MeiraGTx Collaboration
Eli Lilly and Company announced a strategic licensing deal with MeiraGTx to develop gene therapies for eye diseases, marking a significant expansion into...
Eli Lilly Enters $1.2B Licensing Deal for RNAi Metabolic Disease Therapeutics
Eli Lilly and Company has entered into a significant research and licensing agreement with SanegeneBio to discover, develop, and commercialize RNA interference...
Eli Lilly's Stock Price Target Increased to $1,100 by BMO Capital
BMO Capital Markets has raised its price target for Eli Lilly to $1,100 from $930, maintaining an Outperform rating. This significant increase is attributed to...
Eli Lilly Stock Rises on Substantial Progress Announcement
On November 4, 2025, Eli Lilly and Company shares rose 1.13% to $906.69, continuing a strong multi-day rally. The price movement was driven by news that the...
Eli Lilly and Novo Nordisk Reportedly Nearing US Deal to Lower Obesity Drug Prices for Medicare Coverage
Eli Lilly and Novo Nordisk are reportedly nearing a deal with the White House to lower the prices of their popular obesity drugs in exchange for securing...
Eli Lilly Announces $3 Billion Investment in New Netherlands Manufacturing Facility
Eli Lilly and Company has announced plans to build a new $3 billion (€2.6 billion) manufacturing facility in Katwijk, the Netherlands. The site, located within...